OCIN Research offers CEC organization and implementation to enable the independent adjudication of clinical events, conforming to regulatory requirements within single or multi-center, national or international clinical trials.
OCIN clinical evaluation committee play a very important role to make sure the data are accurate and free of bias as possible by its assessment. A strong team has been established based on DIRECT-MT trial since 2018, which is responsible for important clinical events and primary outcome adjudication. There are more than 30 accredited, independent members until 2023 who are neurologist. It is committed to providing first rate service and help assure scientific validity of both Investigator Initiated Trials (IITs) and pre-market studies.
